EMVision Medical Devices Ltd
EMV.AX
Australian Securities Exchange1.57
AUD
+0.00
- -
EMVision Medical Devices Ltd
EMV.AX
(Australian Securities Exchange)
Recent
price
1.57
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- EMVision Medical Devices Ltd is an Australian medical device company specializing in developing and commercializing portable neurodiagnostic imaging systems primarily for stroke diagnosis and monitoring. The company's core products include the emu™ brain scanner, a bedside electromagnetic imaging device that uses ultra-high frequency radio waves and AI-powered algorithms to quickly and safely identify stroke types; and the First Responder Brain Scanner, an ultra-lightweight device designed for pre-hospital use by paramedics in ambulances to enable rapid stroke diagnosis on-site. EMVision’s technology is non-invasive, portable, radiation-free, and intended for deployment in intensive care units, stroke wards, rural emergency departments, and ambulance services. Founded in 2017 and headquartered in Macquarie Park, Australia, EMVision operates primarily in Australia and is advancing clinical trials in the United States as part of its strategic market expansion. In the last two years, EMVision has executed several significant strategic initiatives, including a $10 million investment and strategic equity partnership with Keysight Technologies that accelerates clinical trial efforts and scales production capacity for the emu™ device. The company is conducting a pivotal validation trial to support upcoming FDA regulatory submissions targeted for 2026, aiming for expanded use cases beyond stroke, such as traumatic brain injury. EMVision also secured a $3 million grant from the Australian government for regional stroke care studies and initiated new workflow assessment and data collection studies for its First Responder Brain Scanner. These efforts underscore a clear strategic shift toward commercializing and scaling their neuroimaging technology in both hospital and pre-hospital settings globally. EMVision’s product portfolio leverages an innovative electromagnetic microwave imaging technology platform with an optimized antenna array and machine learning-based image processing algorithms to provide rapid neurodiagnostic outputs at the point of care. Their devices require no special infrastructure, are easy to operate with minimal training, and aim to reduce the time to diagnosis in critical stroke and neurological emergencies. The company collaborates with academic institutions such as the University of Queensland for research and product development and maintains a focus on expanding market penetration across Australia, the United States, and potentially other international healthcare markets. EMVision continues to develop and refine its product pipeline to address a large addressable market of stroke and brain injury patients globally.